97. Ulcerative colitis Clinical trials / Disease details


Clinical trials : 2,630 Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031200103
01/09/202001/09/2020Alginate combined fecal microbiota transplantation for ulcerative colitisSingle center randomized study: Alginate combined fecal microbiota transplantation for ulcerative colitis Ulcerative colitis
Ulcerative colitis
A-FMT plus algin acid therapy arm
Patients are performed Colonoscopy before participating in this clinical research and make sure the patients is eligible. Patient undergoes FMT two days after AFM therapy. Approximately 150 g to 200 g of fresh stool provided in advance from a donor is dissolved in 500 ml of physiological saline, and the treated stool that has been processed to remove excess residues and the like through a filter is stored frozen at minus 80 degree celsius. The diluted and filtered fecal suspension with dextrin added is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site. For the next 8weeks, patients take algin acid two times a day every single day.

A-FMT plus placebo arm
Patients are performed Colonoscopy before participating in this clinical research and make sure the patients is eligible. Patient undergoes FMT two days after AFM therapy. Approximately 150 g to 200 g of fresh stool provided in advance from a donor is dissolved in 500 ml of physiological saline, and the treated stool that has been processed to remove excess residues and the like through a filter is stored frozen at minus 80 degree celsius. The diluted and filtered fecal suspension with dextrin added is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site. For the next 8weeks, patients take Placebo two times a day every single day.
Ishikawa DaiNULLRecruiting>= 20age oldNot applicableBoth60N/AJapan
2NCT02994836
(ClinicalTrials.gov)
April 21, 201724/10/2016GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic EvaluationCrohn's Disease;Inflammatory Bowel Disease;Ulcerative ColitisBiological: Anti-TNF: Infliximab (Infusion);Drug: Anti-TNF discontinuation: Physiological saline solution;Biological: Anti-TNF:Adalimumab (Subcutaneus)Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaNULLCompleted18 YearsN/AAll139Phase 4Spain
3JPRN-jRCTs031180415
01/02/201722/03/2019A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel diseaseSingle center non-randomized study: A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease)
Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease)
AFM therapy arm : three antibiotics, amoxicillin (1500 mg/day), fosfomycin (3000 mg/day) and metronidazole (750 mg/day) are administered orally to patients for 2 weeks. For pediatric patients, amoxicillin (50mg/kg), fosfomycin (120mg/kg) and metronidazole (20mg/kg) are administered orally for 2 weeks (the upper limit is the same amount as adults).
FMT arm : Approximately 150 to 250 g of donor stool is diluted with saline (500 mL) and filtered to remove crude components. The diluted and filtered fecal suspension is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site.
A-FMT arm : Patient undergoes FMT two days after AFM therapy.
Ishikawa DaiNULLRecruiting>= 6age oldNot applicableBoth120N/AJapan
4NCT02998112
(ClinicalTrials.gov)
December 201613/12/2016Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral TubingUlcerative ColitisDrug: fecal microbiota transplantation;Drug: SalineThe Second Hospital of Nanjing Medical UniversityFourth Military Medical University;First Hospital of Guangzhou;Daping Hospital and the Research Institute of Surgery of the Third Military Medical University;Zhongshan Hospital Xiamen UniversityRecruiting18 Years65 YearsBoth188Phase 4China
5NCT02487238
(ClinicalTrials.gov)
November 201525/6/2015Pediatric FEcal Microbiota Transplant for Ulcerative ColitisA Single-Blind, Randomized, Placebo-Controlled Trial of Human Fecal Microbiota Transplantation for the Therapy of Pediatric Ulcerative Colitis and Inflammatory Bowel Disease UnclassifiedInflammatory Bowel Disease;Ulcerative ColitisBiological: Fecal Microbiota Enema;Biological: Normal Saline EnemaMcMaster Children's HospitalLondon Health Sciences Centre;St. Justine's HospitalCompleted3 Years17 YearsAll35Phase 1Canada
6NCT02084550
(ClinicalTrials.gov)
September 20155/3/2014Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative ColitisAmino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis: a Randomized, Assessor-blinded, Placebo-controlled TrialUlcerative ColitisDietary Supplement: Vaminolac;Other: SalineAarhus University HospitalNULLActive, not recruiting18 Years50 YearsAll8N/ADenmark
7NCT02442037
(ClinicalTrials.gov)
May 20156/5/2015Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative ColitisSafety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Active Ulcerative Colitis.Ulcerative ColitisBiological: UCMSC group;Other: Control group(Normal saline)Affiliated Hospital to Academy of Military Medical SciencesIvy Institute of Stem Cells Co. LtdRecruiting18 Years65 YearsBoth30Phase 1/Phase 2China
8NCT00656890
(ClinicalTrials.gov)
April 20084/4/2008A Study of MDX-1100 in Subjects With Active Ulcerative ColitisA Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative ColitisUlcerative ColitisBiological: sterile saline for injection;Biological: MDX-1100Bristol-Myers SquibbNULLCompleted18 YearsN/ABoth110Phase 2United States;Canada;Czech Republic;Hungary;Latvia;Romania;Russian Federation;Ukraine